Cancer Immunotherapy and Medical Imaging Research Trends from 2003 to 2023: A Bibliometric Analysis

Figures & data

Figure 1 The flowchart illustrating the search strategy and selection process in Cancer Immunotherapy and Medical Imaging.

Figure 2 Annual number of publications on Cancer Immunotherapy and Medical Imaging.

Table 1 Top10 Productive Countries in Cancer Immunotherapy and Medical Imaging

Ranking	Frequency	Centrality	Country	Region
1	265	0.49	USA	North America
2	170	0.04	PEOPLES R CHINA	Asia
3	75	0.15	GERMANY	Europe
4	44	0.10	ENGLAND	Europe
5	40	0	JAPAN	Asia
6	39	0.04	ITALY	Europe
7	34	0.03	FRANCE	Europe
8	28	0.07	AUSTRALIA	Oceania
9	27	0.16	NETHRLANDS	Europe
10	25	0.12	SPAIN	Europe

Figure 3 Cooperation map of countries/regions in Cancer Immunotherapy and Medical Imaging.

Table 2 Top10 Productive Institutions in Cancer Immunotherapy and Medical Imaging

Ranking	Frequency	Centrality	Institution	Country
1	33	0.10	Harvard University	USA
2	27	0.05	University of Texas System	USA
3	27	0.04	Mayo Clinic	USA
4	25	0.10	University of California System	USA
5	25	0.07	Harvard Medical School	USA
6	22	0.04	Helmholtz Association	Germany
7	21	0.03	UTMD Anderson Cancer Center	USA
8	17	0.03	Brigham & Women’s Hospital	USA
9	15	0.09	Memorial Sloan Kettering Cancer Center	USA
10	13	0.07	Chinese Academy of Sciences	CHINA

Table 3 Top10 Authors and Co-Cited Authors in Cancer Immunotherapy and Medical Imaging

Rank	Frequency	Year	Author	Frequency	Year	Co-Cited Author	Centrality
1	5	2008	Pittock, Sean J^Citation28	43	2009	TOPALIAN SL^Citation38	≤0.01
2	4	2018	Abu-sbeih, Hamzah^Citation29	40	2015	GRAUS F^Citation39
3	4	2013	Flanagan, Eoin P^Citation30	38	2017	DALMAU J^Citation40
4	3	2006	Wall, Jonathan S^Citation31	34	2013	EISENHAUER EA^Citation41
5	3	2022	Zhang, Hua^Citation32	31	2019	ROBERT C^Citation42
6	3	2014	Sigurdsson, Einar M^Citation33	30	2017	WOLCHOK JD^Citation43
7	3	2006	Weiss, Deborah T^Citation34	30	2015	NISHINO M^Citation44
8	3	2014	Gambhir, Sanjiv S^Citation35	29	2019	HODI FS^Citation45
9	3	2017	Ascierto, Paolo Antonio^Citation36	28	2015	RIBAS A^Citation46
10	3	2023	Sun, Wei^Citation37	26	2019	BRAHMER JR^Citation47

Figure 4 Cooperation map of authors in Cancer Immunotherapy and Medical Imaging.

Figure 5 Top 20 references with the strongest citation bursts in Cancer Immunotherapy and Medical Imaging.

Figure 6 Timeline viewer of references related to Cancer Immunotherapy and Medical Imaging.

Table 4 Top10 Co-Cited Journals in Cancer Immunotherapy and Medical Imaging

Ranking	Co-Cited Journal	Frequency	IF (2024)	Country
1	The New England Journal of Medicine	315	24.1	USA
2	Journal of Clinical Oncology	232	11.5	USA
3	Clinical Cancer Research	202	11.5	USA
4	The Lancet	170	168.9	ENGLAND
5	Proceedings Of The National Academy Of Sciences Of The United States Of America	167	11.1	USA
6	Cancer Research	159	11.2	USA
7	Nature	157	64.8	ENGLAND
8	The Lancet Oncology	155	51.1	USA
9	Nature Medicine	151	82.9	USA
10	Plos One	144	3.7	USA

Table 5 Top ten Keywords in Cancer Immunotherapy and Medical Imaging

Ranking	Frequency	Centrality	Keyword
1	80	0.30	Immunotherapy
2	75	0.14	Cancer
3	60	0.10	Therapy
4	46	0.06	Expression
5	46	0.14	Antibody
6	42	0.07	Diagnosis
7	34	0.03	Nivolumab
8	31	0.13	Cells
9	30	0.04	Survival
10	29	0.05	Chemotherapy

Figure 7 (A) A visual map for CiteSpace network among keywords. (B) The cluster of keywords in the studies of Cancer Immunotherapy and Medical Imaging. (C) Top 20 keywords with the strongest citation bursts in Cancer Immunotherapy and Medical Imaging.

Figure 8 Timeline viewer of keywords related to Cancer Immunotherapy and Medical Imaging.

Geschwind MD, Tan KM, Lennon VA, et al. Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol. 2008;65(10):1341–1346. doi:10.1001/archneur.65.10.1341

 PubMedGoogle Scholar

G C, R A, Dp C, et al. Non-small-cell lung cancer. Nat Rev Dis Primer. 2015:1. doi:10.1038/nrdp.2015.9

 Web of Science ®Google Scholar

Tian Y, Abu-Sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Hepatitis. Adv Exp Med Biol. 2018;995:159–164. doi:10.1007/978-3-030-02505-2_8

 PubMed Web of Science ®Google Scholar

La Puma D, Llufriu S, Sepúlveda M, et al. Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. J Neurol Sci. 2015;352(1–2). doi:10.1016/j.jns.2015.03.038

 PubMed Web of Science ®Google Scholar

Flanagan EP, Keegan BM. Paraneoplastic myelopathy. Neurol Clin. 2013;31(1):307–318. doi:10.1016/j.ncl.2012.09.001

 PubMed Web of Science ®Google Scholar

Dalmau J. The case for autoimmune neurology. Neurol Neuroimmunol Neuroinflammation. 2017;4(4):e373. doi:10.1212/NXI.0000000000000373

 PubMed Web of Science ®Google Scholar

O’Nuallain B, Hrncic R, Wall JS, Weiss DT, Solomon A. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol Baltim Md 1950. 2006;176(11):7071–7078. doi:10.4049/jimmunol.176.11.7071

 Google Scholar

Jamal R, Goodwin RA, Tu D, Walsh W, Lacombe D, Eisenhauer EA. Performance of multinomial designs in comparison with response-based designs in non-randomized Phase II trials of targeted cancer agents. Ann Oncol off J Eur Soc Med Oncol. 2013;24(7):1936–1942. doi:10.1093/annonc/mdt122

 PubMed Web of Science ®Google Scholar

Zhang H, Zhao H, Huang Y, Sun G, Zhang Y. Microenvironment-activatable cascaded responsive carbonized polymer dots as a theranostic platform for precise rapamycin delivery to potentiate the synergy of chemotherapy and γδ T cells-mediated immunotherapy against tumor. Appl Mater Today. 2022;26:101364. doi:10.1016/j.apmt.2022.101364

 Web of Science ®Google Scholar

Gauci ML, Lanoy E, Champiat S, et al. Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin Cancer Res off J Am Assoc Cancer Res. 2019;25(3):946–956. doi:10.1158/1078-0432.CCR-18-0793

 PubMed Web of Science ®Google Scholar

Sigurdsson EM. Tau immunotherapy and imaging. Neurodegener Dis. 2014;13(2–3):103–106. doi:10.1159/000354491

 PubMed Web of Science ®Google Scholar

N J, W X, Km W, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol off J Am Soc Clin Oncol. 2017;35(7). doi:10.1200/JCO.2016.68.2005

 Google Scholar

Js W, Sj K, P M, et al. 2006; Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med off Publ Soc Nucl Med. 47(12):2016–2024.

 PubMed Web of Science ®Google Scholar

Krajewski KM, Nishino M, Ramaiya NH, Choueiri TK. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. AJR Am J Roentgenol. 2015;204(3):W282–W288. doi:10.2214/AJR.14.13236

 PubMed Web of Science ®Google Scholar

Pan Y, Volkmer JP, Mach KE, et al. Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. Sci Transl Med. 2014;6(260):260ra148. doi:10.1126/scitranslmed.3009457

 PubMed Web of Science ®Google Scholar

Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17–65. doi:10.1210/er.2018-00006

 PubMed Web of Science ®Google Scholar

McArthur GA, Mohr P, Ascierto PA, et al. Health care resource utilization and associated costs among metastatic cutaneous melanoma patients treated with Ipilimumab (INTUITION Study). oncologist. 2017;22(8):951–962. doi:10.1634/theoncologist.2016-0272

 PubMed Web of Science ®Google Scholar

Ds S, R A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33. doi:10.1016/j.coi.2015.01.006

 Web of Science ®Google Scholar

Sheng R, Sun W, Huang X, et al. Apparent diffusion coefficient MRI shows association with early progression of unresectable intrahepatic cholangiocarcinoma with combined targeted-immunotherapy. J Magn Reson Imaging JMRI. 2023;57(1):275–284. doi:10.1002/jmri.28214

 PubMed Web of Science ®Google Scholar

Naidoo J, Zhang J, Lipson EJ, et al. A multidisciplinary toxicity team for cancer immunotherapy-related adverse events. J Natl Compr Cancer Netw JNCCN. 2019;17(6):712–720. doi:10.6004/jnccn.2018.7268

 PubMed Web of Science ®Google Scholar